Atara Biotherapeutics (ATRA) News Today

The Goldman Sachs Group decreased their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a "sell" rating on the stock in a research note on Wednesday.

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have earned a consensus recommendation of "Hold" from the three research firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating. The average 12-mont

Atara Biotherapeutics (NASDAQ:ATRA) Sees Unusually-High Trading Volume

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have earned an average rating of "Hold" from the three brokerages that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation. The average 1

Atara Biotherapeutics (NASDAQ:ATRA) Shares Gap Down to $9.87

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report)'s stock is set to reverse split before the market opens on Thursday, June 20th. The 1-25 reverse split was announced on Thursday, June 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, June 20th.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - Stock analysts at HC Wainwright upped their Q2 2024 earnings per share estimates for shares of Atara Biotherapeutics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst R. Burns now anticipate

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a research note issued on Wednesday, May 22nd. HC Wainwright analyst R. Burns expects that the biotechnology company w

HC Wainwright reiterated a "neutral" rating on shares of Atara Biotherapeutics in a report on Wednesday.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CFO Eric J. Hyllengren sold 28,648 shares of the company's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $17,761.76. Following the completion of the sale, the chief financial officer now directly owns 645,671 shares in the company, valued at $400,316.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

StockNews.com downgraded Atara Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Monday.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 10,140,000 shares, a decrease of 6.7% from the February 14th total of 10,870,000 shares. Based on an average daily trading volume, of 3,640,000 shares, the short-interest ratio is currently 2.8 days.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 10,870,000 shares, an increase of 44.4% from the January 31st total of 7,530,000 shares. Based on an average daily volume of 3,690,000 shares, the short-interest ratio is currently 2.9 days.